drugset / Trial / NCT04587128
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
Phase 2
Active not recruiting
34 enrolled
University of Wisconsin, Madison
Doris Duke Charitable Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an alternative treatment strategy to maximize the benefit to inhibition of epidermal growth factor receptor (EGFR) for a highly selected patient population. It will enroll 71 participants with left-sided, unresectable metastatic CRC. Participants will be on study up to 5 years.
Timeline
- Start
- 2020-10-19
- Primary completion
- 2029-10
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg | — |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | — |
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |